[CAS NO. 605-94-7] Coenzyme Q0
PRODUCTS SPECIFICATIONS [605-94-7]
DESCRIPTION [605-94-7]
Overview
| MDL | MFCD00001595 |
|---|---|
| Molecular Weight | 182.18 |
| Molecular Formula | C9H10O4 |
| SMILES | O=C1C(OC)=C(OC)C(C(C)=C1)=O |
Summary
Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea . Coenzyme Q0 induces apoptosis and autophagy , suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling [1] [2] [3] .
In Vitro
Coenzyme Q0 (0-40 µM; 24 h) and inhibits viability and growth of human ovarian carcinoma cells
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) has anti-proliferative activity through induction of G2/M cell-cycle arrest and reduction of cell-cycle regulatory proteins
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 0-30 min; SKOV-3 cells) increases intracellular ROS levels to promote SKOV-3 cell death
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces autophagy by increase accumulation of LC3-II, GFP-LC3 puncta, AVOs formation and Beclin-1/Bcl-2 dysregulation
[1]
.
Coenzyme Q0 (CoQ0) (0-30 µM; 24 h; SKOV-3 cells) induces apoptosis by mitochondrial (caspase-3, PARP and Bax/Bcl-2 dysregulation) and ER stress (caspase-12 and Hsp70) signals
[1]
.
Coenzyme Q0 (CoQ0) (30 µM; 24 h; SKOV-3 cells) suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms
[1]
.
Coenzyme Q0 (CoQ0) (0-10 µM; 0.5-18 h; RAW264.7 cells) regulates NFκB/AP-1 activation and enhances Nrf2 stabilization
[2]
.
Coenzyme Q0 (CoQ0) (5 µM; 0-12 h; EA.hy 926 cells) has anti-angiogenic activity in EA.hy 926 cells
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 10, 20, 30 and 40 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased viability with the IC 50 values of 26.6 µM, 27.3 µM and 28.4 µM for SKOV-3, A2780 and A2870/CP70 cells, respectively. |
Cell Cycle Analysis [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 10, 20 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Arrested cell cycle at G2/M phase and reduced cell-cycle proteins in SKOV-3 cells. |
Apoptosis Analysis [1]
| Cell Line: | SKOV-3, A2780 and A2870/CP70 cells |
| Concentration: | 0, 5, 15 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Promoted the conversion of LC3–1 to LC3-II and increased the LC3-II accumulation. Increased Bax/Bcl-2 ratio in a dose-dependent manner. |
Apoptosis Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 0, 10, 20 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Had the percentage of early apoptotic cells are 25.1%, 34% and 36% for 10, 20 and 30 µM, respectively. |
Western Blot Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 0, 5, 15 and 30 µM |
| Incubation Time: | 24 hours |
| Result: | Activated of caspase-3 and cleavaged of PARP. Increased the expressions of caspase-12, HSP-70 and Bax in a dose-dependent manner, decreased the expressions of Bcl-2. |
Western Blot Analysis [1]
| Cell Line: | SKOV-3 cells |
| Concentration: | 30 µM |
| Incubation Time: | 24 hours |
| Result: | Decreased the phosphorylated HER-2 (Y1221) levels, p-AKT (Ser473) and p-mTOR (S2448) levels. |
Western Blot Analysis [2]
| Cell Line: | RAW264.7 cells |
| Concentration: | 0, 2.5, 5 and 10 µM |
| Incubation Time: | 0.5-18 hours |
| Result: | Inhibited iNOS/COX-2 protein expressions with reductions of NO, PGE2, TNF-α and IL-1β secretions. |
Western Blot Analysis [3]
| Cell Line: | EA.hy 926 cells |
| Concentration: | 5 µM |
| Incubation Time: | 0, 1, 3, 6 and 12 hours |
| Result: | Increased expressions of heme oxygenase-1 (HO-1) and γ-glutamylcysteine synthetase (γ-GCLC), inhibits protein expressions of matrix metalloproteinase-9 (MMP-9), reduces TNF-α-induced nuclear translocation and transcriptional activation of nuclear factor-κB (NF-κB). |
In Vivo
Coenzyme Q0 (CoQ0) (1.5 and 2.5 mg/kg; i.p.; once every four days, for 52 d) suppresses tumor growth in SKOV-3 xenografted nude mice
[1]
.
Coenzyme Q0(CoQ0) (5 mg/kg; p.o.; for 4 h) has anti-inflammatory activities through Nrf2 activation and NFκB inhibition in liver and spleen of LPS-treated mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | SKOV-3 xenografted nude mice [1] |
| Dosage: | 1.5 and 2.5 mg/kg |
| Administration: | Intraperitoneal injection; Once every four days, for 52 days |
| Result: | Inhibited the tumor growth at 1.5 and 2.5 mg/kg. |
| Animal Model: | LPS-treated female FVB mice [2] |
| Dosage: | 5 mg/kg |
| Administration: | Oral administration; for 4 hours |
| Result: | Down-regulates inflammatory genes in liver and spleen tissues of LPS injected mice. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 274.45 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.4891 mL | 27.4454 mL | 54.8908 mL |
| 5 mM | 1.0978 mL | 5.4891 mL | 10.9782 mL |
| 10 mM | 0.5489 mL | 2.7445 mL | 5.4891 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1.67 mg/mL (9.17 mM); Clear solution
References
- [1] Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.
- [2] Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.
- [3] Yang HL, et, al. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem Pharmacol. 2015 Nov 1;98(1):144-56.
Synonyms